Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Debt / NOTE 0.750% 5/1
-
Number of holders
-
25
-
Total 13F principal, excl. options
-
66,591,000
-
Principal change
-
-3,924,065
-
Total reported value, excl. options
-
$65,027,776
-
Value change
-
-$3,765,173
-
Number of buys
-
8
-
Number of sells
-
-6
-
Price
-
$0.9731
Significant Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 as of Q4 2022
29 filings reported holding 53220KAF5 - LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 as of Q4 2022.
LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 has 25 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $66,591,000 of principal
.
Largest 10 bondholders include OAKTREE CAPITAL MANAGEMENT LP ($20,994,000 of principal), CAPSTONE INVESTMENT ADVISORS, LLC ($7,500,000 of principal), PALISADE CAPITAL MANAGEMENT, LP ($6,270,000 of principal), Voya Investment Management LLC ($5,000,000 of principal), Russell Investments Group, Ltd. ($4,369,000 of principal), WESTWOOD HOLDINGS GROUP INC ($4,000,000 of principal), Radcliffe Capital Management, L.P. ($3,117,000 of principal), SCHRODER INVESTMENT MANAGEMENT GROUP ($3,000,000 of principal), JPMORGAN CHASE & CO ($2,687,000 of principal), and TORONTO DOMINION BANK ($2,500,000 of principal).
This table shows the top 25 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.